Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 1045Lung Neoplasms 803Small Cell Lung Carcinoma 193Breast Neoplasms 158Colorectal Neoplasms 157Neoplasms 128Melanoma 116Ovarian Neoplasms 111Pancreatic Neoplasms 107Stomach Neoplasms 95Neoplasm Metastasis 89Esophageal Neoplasms 77Squamous Cell Carcinoma of Head and Neck 75Prostatic Neoplasms 66Uterine Cervical Neoplasms 65Head and Neck Neoplasms 65Endometrial Neoplasms 61Triple Negative Breast Neoplasms 59Colonic Neoplasms 58Carcinoma, Renal Cell 58Mesothelioma, Malignant 48Adenocarcinoma of Lung 48Urinary Bladder Neoplasms 47Carcinoma, Hepatocellular 46Mesothelioma 42Sarcoma 40Brain Neoplasms 40Liver Neoplasms 38Disease 34NSCLC 33

Interventions

Pemetrexed 2Carboplatin 2camrelizumab 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Non Squamous Non Small Cell Lung Cancer × Thoracic × Clear all
NCT06687369 2026-03-11

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

mAbxience Research S.L.

Phase 3 Recruiting
726 enrolled
Thoracic

Non Squamous Non Small Cell Lung Cancer

NCT06939595 2025-04-23

A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

Celltrion

Phase 3 Recruiting
606 enrolled
Thoracic

Non Squamous Non Small Cell Lung Cancer

NCT05841472 2023-08-30

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

CrystalGenomics, Inc.

Phase 2 Recruiting
60 enrolled
Thoracic

Non Squamous Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡